| Abstract: |
The pharmacokinetics (PK) of nanoparticles is believed to be controlled by a complex array of interrelated physicochemical and biological factors, and an in-depth knowledge of the nanoparticle-organ interaction is critical for not only the nanoplatform design but also its potential clinical translation. Since, it largely defines their in vivo performance and potential toxicity. It is generally accepted that the biodistribution of nanoparticle is determined by the hydrodynamic size, shape, surface chemistry, in vivo stability and the administration route of the injected nanoparticles. The optimal characteristics for the nanoparticle, to be used in the clinical field, is being investigated and not yet clearly known. So far, highly sensitive and quantitative nuclear imaging is perhaps the best tool for assessing the PK profile of radiolabeled nanoparticles in vivo. However, since nuclear imaging technique detects the radioisotopes but not the nanoparticles themselves, the radiolabeling technique and the in vivo stability of the radiolabeled nanoparticles are critical and needs to be well addressed to achieve a reliable evaluation of nanoparticle fate in vivo. |
